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Abstract
 
Colonization of the nasopharynx is the initial step in all infections caused by 
 
Streptococcus pneu-
moniae
 
. The antibody response to carriage was examined in an experimental model of human
colonization in healthy adults. Asymptomatic colonization was detected in 6/14 subjects
and continued for up to 122 d. Susceptibility to carriage did not correlate with total serum
immunoglobulin (Ig)G to the homotypic capsular polysaccharide. All of the colonized subjects,
in contrast, developed a serum IgG and secretory IgA response to a 22 kD protein, whereas 7 of
8 subjects who did not become colonized had preexisting antibody to this protein. Analysis of
the 22 kD protein identified it as the NH
 
2
 
-terminal region of pneumococcal surface protein A
(PspA). Our findings provide evidence for the role of antibody to this protein fragment in
preventing pneumococcal carriage by humans.
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Introduction
 
Streptococcus pneumoniae
 
 (the pneumococcus) colonizes the
mucosal surface of the human nasopharynx. Infection occurs
when the organism spreads beyond this niche into normally
sterile parts of the respiratory tract or, in the most serious
cases, into the bloodstream. Colonization, therefore, is the
crucial first step in the pathogenesis of all pneumococcal
disease (1).
The acquisition and widespread dissemination of resis-
tance to 
 
 
 
-lactam antibiotics as well as resistance to other
classes of antimicrobials has complicated the treatment of
pneumococcal infection (2). This problem has emphasized
the need for preventive strategies against this common
pathogen. The immunodominant antigen of the pneumo-
coccus is the capsular polysaccharide (PnPS) of which there
are 90 known types. Antibody to the PnPS of a given type
is thought to provide protection only to an isolate of the
homologous type (3). Although colonization results in an
increase in type-specific serum antibody, it remains unclear
whether carriage is an immunizing event for a given type
(4). Immunization with a mixture of PnPS of the most
prevalent types is protective in adults; but because young
children do not respond to T cell–independent polysaccha-
ride antigens, this prophylactic strategy is unsuccessful in
the population at highest risk of disease. This finding has led
to the recent introduction of a vaccine based on conjugate
technology that couples PnPS to an immunogenic carrier
protein resulting in a shift to a T cell–dependent immune
response (5). To produce an epidemiologically effective
PnPS-protein conjugate vaccine, however, multiple types
of the 90 known PnPSs must be conjugated to a protein
carrier. This requirement results in a complex and expensive
multi-component vaccine with restricted potential efficacy
because of the limited number of PnPS types that can be
included in any single formulation, the possibility of sero-
type replacement, and the high titer type-specific antibody
response to some but not to all types (6, 7).
The focus of this study is the identification of pneumo-
coccal proteins that are immunogenic during carriage. A
pneumococcal protein vaccine that would specifically in-
terfere with carriage would avoid many of the problems
associated with vaccines based on PnPS and could poten-
tially have the greatest impact on the prevention of disease.
A number of pneumococcal proteins that have been shown
to induce opsonophagocytic antibodies or to offer some
degree of protection in murine models are currently under
investigation as novel vaccine candidates (8). Mice, how-
ever, are not naturally colonized by 
 
S. pneumoniae
 
 and,
when subjected to infection via artificial routes, are variably
susceptible to a limited number of pneumococcal types (9).
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To avoid the limitations of animal models, this study uti-
lizes experimental human colonization and shows that the
presence of serum antibody to a single pneumococcal pro-
tein correlates with susceptibility to carriage.
 
Materials and Methods
 
Carriage Model.
 
Pneumococcal carriage was studied at the
Respiratory Pathogens Research Unit, Baylor College of Medi-
cine according to an Institutional Review Board approved pro-
tocol and written informed consent acknowledging the use of
an infectious agent and the availability of treatment for any signs
of infection. 14 healthy adults were given a 0.1 ml intranasal in-
oculum to each naris containing 5,000 CFU (FS92, 123, 162,
177), 7,000 CFU (FS1, 62, 80, 105, 129, 138), or 17,000 CFU
(FS11, 31, 150, 163) of a type 23F clinical isolate, P833. This
penicillin-sensitive isolate was obtained from a child with otitis
media by tympanocentesis and stored at –80
 
 
 
C after minimal
passage. Study inclusion criteria included; age between 18 and
40 yr old, HIV seronegative, nonpregnant, nonsmoking, an in-
tact spleen, consume 
 
 
 
3 alcoholic beverages per day, no history
of pneumococcal vaccination, no penicillin allergy, no history
of recurrent respiratory tract infections or chronic illnesses, no
close contact with individuals at increased risk for pneumococ-
cal disease, and lack pneumococcal colonization for 4 wk before
the inoculation as determined by nasal and throat cultures. A
separate study was performed with a clinical type 6B isolate. Se-
rum and nasal washes were obtained before inoculation and ev-
ery 2 wk after inoculation until pneumococcal carriage was no
longer detected in nasal or throat cultures in two consecutive
visits.
 
Pneumococcal Strains and Products.
 
All pneumococcal isolates
and strains were grown in semisynthetic media (C
 
 
 
Y media, pH
6.8) until mid-log phase was reached (OD
 
620
 
 
 
 
 
 0.4) (10). Sero-
type was confirmed by using the quellung reaction with type spe-
cific antisera purchased from the Staten Serum Institut. Culture
supernatants were collected after centrifugation for 20 min at
900 
 
g
 
. The bacterial pellet was washed with an equal volume of
cold PBS (pH 7.5) and then resuspended in 5% of the original
culture volume of cold PBS for lysis by sonication.
 
Western Blot Analysis.
 
Bacterial sonicates and concentrated
supernatants were used in Western blot analysis by using 10 
 
 
 
g
total protein/lane and separated on SDS-PAGE gels (7.5–15%).
After electrophoretic transfer onto an Immobilon-P membrane
(Millipore), transfer was visualized by staining membranes with
Ponceau S (Sigma-Aldrich). Individual lanes were incubated 16 h
at 25
 
 
 
C with pre- or postinoculum sera (diluted 1:10,000) or na-
sal washes (diluted 1:500) from individual volunteers. Protein-
specific antibodies were detected with goat anti–human IgG or
IgA specific antisera conjugated to alkaline phosphatase (Sigma-
Aldrich). 20-fold concentrated pneumococci were treated with
PBS containing 2% choline chloride in PBS for 20 min at 4
 
 
 
C to
isolate the choline-binding proteins. N-terminal sequencing was
determined by Edman degradation.
 
DNA Sequencing.
 
Genomic DNA was isolated as described
previously (11). The 
 
pspA
 
 gene was amplified by PCR with prim-
ers LSM12 and SKH3, which bind to conserved flanking regions
(12). Primers, 5
 
 
 
-AACTGAAGAGAAAGCAAAGC-3
 
 
 
 and 5
 
 
 
-
CGTCTAACTCATCAATCTTATCAC-3
 
 
 
, internal to the orig-
inal primers were used to verify both strands of the sequence of
the 
 
pspA
 
 of strain P833. Sequence analysis was repeated on DNA
generated in four independent PCR amplifications.
 
Enzyme-linked Immunosorbant Assays.
 
A PCR product con-
taining the nucleotide sequence of 
 
pspA
 
 from P833 and unique
restriction enzyme sites was amplified with the use of primers, 5
 
 
 
-
CCGGAATTCTCTCAGCTTCTTCTG-3
 
 
 
 and 5
 
 
 
-GGAAT-
TCCATATGGAAGAAGCTCCC-3
 
 
 
 which contain EcoRI and
a NdeI sites respectively. After digestion and ligation of the PCR
product to the pET28a vector, His-tagged pneumococcal surface
protein A
 
 
 
(PspA)
 
31–189
 
 was expressed in the presence of IPTG and
purified from 
 
E. coli
 
 strain BL21 on an activated His-Bind Resin
column (Novagen). A similar procedure was followed for gener-
ating fragments from the mature PspA from amino acids 31–92,
31–162, and 87–162.
The purified His-tagged PspA
 
31–189
 
 was used to coat 96-well
Immulon 2 High Binding plates (DYNEX Technologies) by in-
cubating 0.5 
 
 
 
g/ml in coating buffer (0.015 M Na
 
2
 
CO
 
3
 
, 0.035 M
NaHCO
 
3
 
, pH 9.6). After overnight incubation at 4
 
 
 
C, the
plates were washed with PBS-Tween 20, blocked with 1% BSA
for 1 h at 37
 
 
 
C, and washed again. Twofold serial dilutions of hu-
man serum were added and then incubated overnight at 4
 
 
 
C.
PspA-specific antibodies were detected by goat anti–human IgG-
alkaline phosphatase (Sigma-Aldrich), developed with pNPP, and
the absorbance at 415 nm recorded. Titers were determined by
calculating the sample dilution at which the absorbance was equal
to 0.3. The ELISA to detect antibody to the type 23F capsular
polysaccharide followed the protocol established by the Centers
for Disease Control.
 
Lactoferrin Binding Assay.
 
Fractions containing choline-bind-
ing proteins, His-tagged PspA
 
31–189
 
, or purified human lactoferrin
(Sigma-Aldrich) were separated on 12.5% SDS-PAGE gels and
transferred to Immobilon-P membranes. The ability of PspA to
bind human lactoferrin was assessed by using a previously de-
scribed protocol (13, 14).
 
Infant Rat Colonization.
 
The model of pneumococcal car-
riage in infant rats has been described previously (15). Cells of a
streptomycin-resistant transformant of strain P833 were mixed
with an equal number of cells of the last isolate cultured from
subject FS1 and inoculated into the nares of 2-d-old Sprague-
Dawley rats (10
 
6
 
 cfu/pup). Nasal washes were examined for 7 d
after inoculation by plating on media with and without strepto-
mycin (200 
 
 
 
g/ml) to quantify the carriage of each strain.
 
Results
 
Antibody Response to Pneumococcal Proteins.
 
14 healthy adults
received an intranasal inoculation of a type 23F clinical
isolate. 6 of 14 volunteers carried the type 23F pneumo-
coccus asymptomatically with a duration of carriage rang-
ing from 27–122 d (colonized group); colonization could
not be detected in the remaining eight subjects (uncolo-
nized group). Susceptibility to colonization was not pre-
dicted by the preinoculation level of serum IgG against the
type 23F capsular polysaccharide (PS-23F) as determined
by ELISA (Fig. 1 A). On the basis of this unexpected ob-
servation, we examined the antibody response to pneumo-
coccal proteins. Western blot analysis of whole cell soni-
cates of the inoculated strain (P833) were used to compare
patterns of reactivity in serum before inoculation (preinoc-
ulation) with those of the earliest time point that colo-
nization was not detected (postinoculation) from both col-
onized and uncolonized subjects. Uncolonized subjects
demonstrated no detectable change in the reactivity of se- 
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rum IgG pre- and postinoculation (Fig. 2 A). In contrast,
6/6 colonized subjects developed an IgG response to a
band migrating at 22 kD. Although there were increases in
reactivity to other bands after carriage, preinoculation se-
rum IgG from the colonized group did not demonstrate re-
activity to the 22 kD band. In addition, 7/8 subjects that
did not become colonized had preexisting IgG recognizing
this band (
 
P 
 
 
 
 0.004 compared with colonized group,
Fisher’s exact test). A similar pattern of IgG reactivity to
this band was seen in immunoblots of nasal washes (unpub-
lished data). Nasal washes were also used to characterize the
secretory IgA response (Fig. 2 B). 6/6 colonized versus 1/8
uncolonized subjects acquired or increased sIgA reactivity
to the 22 kD band (
 
P 
 
 
 
 0.004, Fisher’s exact test). These
results demonstrate a correlation between the immune re-
sponse to this band and susceptibility to carriage.
 
Identification and Characterization of the 22 kD Band.
 
Further analysis showed that 22 kD band was the most
abundant product in culture supernatants (Fig. 2 B, lane PS).
After additional purification of culture supernatants by
size fractionation, the NH
 
2
 
-terminal sequence, EEAP-
VAKQFQAERDY, a 14/15 match to a database entry to
the NH
 
2
 
 terminus of the mature form of PspA from a type
23F strain, was obtained. This finding was unexpected, as
the size of PspA normally ranges from 67–99 kD (12). Se-
quencing of the 
 
pspA
 
 gene from P833 revealed a deletion of
Figure 1. Serum antibody response to (A) type 23F capsular polysaccha-
ride (PS-23F) and (B and C) the recombinant NH2-terminal fragment of
PspA (PspA31–189) from strain P833 used as the inoculum in experimental
human carriage studies. PS-23F or PspA31–189 was used in ELISAs to de-
termine the PS-23F or PspA31–189 specific IgG titers in uncolonized and
colonized subjects (FS#) before (white bars) and at first time point that
colonization was no longer detected (black bars). Values shown in panel
A are ng/ml amounts of antibody and are from a representative experi-
ment, in B are the mean antibody titers  SEM for four independent ex-
periments, and in C are a representative determination of the kinetics of
the serum IgG response in colonized patients. ^ indicates point of inocu-
lation. The final time point for each subject (FS#) was 2 wk after the last
positive throat or nasal culture. 
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a single adenosine residue within a group of eight tandem
adenosines around position 540 that created a frame-shift
leading to premature termination of the mature protein at
amino acid 189 (Fig. 3). Thus, the truncated protein,
PspA
 
31–189
 
, lacks the choline-binding domain that acts to an-
chor PspA to the cell surface and prevent its secretion (16).
 
Serum IgG Response to PspA
 
31
 
 
 
189
 
.
 
The immune response
to the PspA fragment was quantified by ELISA by using
recombinant PspA
 
31–189
 
 from P833 (Fig. 1 B). Comparison
of IgG titers to PspA
 
31–189
 
 in pre- and postinoculation se-
rum showed that 7/8 and 2/6 subjects in the uncolonized
and colonized groups respectively had preexisting anti-
body (1/titer 
 
  
 
1,000; 
 
P 
 
  
 
.09, Fisher’s exact test). Serum
IgG detected by ELISA correlated with results from West-
ern analysis with the exception of preinoculation IgG to
PspA
 
31–189
 
 which was observed in subjects FS80 and FS163
only by ELISA. All of the colonized but none of the
uncolonized subjects developed a significant rise in IgG
levels to the PspA
 
31–189
 
 (
 
P 
 
  
 
0.0003, Fisher’s exact test).
When subfragments of PspA
 
31–189
 
 were analyzed, the IgG
Figure 2. Western blot analysis
demonstrating the antibody re-
sponse to pneumococcal proteins.
Antibodies from individual sub-
jects (indicted by FS#) were used
to detect differences in reactivity
in immunoblots incubated with
specimens obtained preinocula-
tion (P) compared with first time
point that colonization was no
longer detected (L). Total pro-
tein as detected by staining with
Ponceau S is shown in lane PS.
An arrow indicates the 22-kD
band to which the antibody re-
sponse correlates with suscepti-
bility to carriage. Size markers
are in kilodaltons. (A) Whole
cell sonicates of the strain used
in experimental human carriage
studies were used to detect differ-
ences in IgG reactivity in serum.
(B) Concentrated (100 ) cul-
ture supernatants from the strain
used in experimental human
carriage studies were used to de-
tect differences in secretory IgA
in nasal washes.
Figure 3. Nucleotide sequence and predicted translation product for an internal region of pneumococcal surface protein A (PspA). (A) database entry
for a type 23F strain (GenBank/EMBL/DDBJ accession no. AF071811), (B) corresponding sequence for P833 used in nasal inoculations showing a
frame-shift mutation within eight adenosines (shown by overlining) causing truncation of PspA as indicated, and (C) corresponding sequence from the
last isolate obtained from subject FS1 which contains a compensatory two base pair deletion restoring expression of full-length PspA. Dash indicates a nu-
cleotide deletion. The nucleotide and amino acid position is shown relative to the initiation codon. 
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response was found to be specific to the hypervariable re-
gion COOH-terminal to amino acid 92 (unpublished data;
reference 12). In contrast to the ELISA results for PspA
 
31–189
 
,
the level of preexisting serum IgG specific to the type 23F
polysaccharide did not correlate with susceptibility to be-
coming colonized (mean IgG preinoculation in uncolonized/
colonized 
 
  
 
2.75 for PspA
 
31–189
 
 versus 1.17 for PS-23F;
Fig. 1). In addition, the colonized group had an average
eightfold increase in IgG to PspA
 
31–189
 
, whereas the average
increase in IgG titer was only twofold to PS-23F during
carriage. The increase in IgG titer to PspA
 
31–189
 
 occurred
by 4 wk postinoculation (Fig. 1 C). As carriage was main-
tained for up to 122 d postinoculation, the rise in the level
of IgG to PspA
 
31–189
 
 does not appear to correlate tempo-
rally with the loss of carriage. Serum from subjects chal-
lenged with an unrelated type 6B pneumococcal isolate
(6/7 colonized) had no significant rise by ELISA in IgG ti-
ters to PspA
 
31–189
 
 from strain P833 suggesting that the anti-
body response to this fragment may be strain specific.
 
Stability of Expression of PspA.
 
The observation that an
isolate expressing a truncated and secreted PspA was still
able to colonize the human nasopharynx was unexpected.
To determine if this characteristic was maintained through-
out the period of carriage, the last isolate from each colo-
nized subject was analyzed. Western blots demonstrated
that pneumococci from 5/6 subjects expressed PspA
 
31–189
 
throughout the entire period of colonization suggesting that
the full-length protein is not essential for maintenance of
the carrier state (Fig. 4 A). The last isolate from subject FS1
(P833-FS1), in contrast, lost expression of the 22 kD band.
Western analysis showed that the loss of the 22 kD band
from P833-FS1 was associated with the acquisition of a
prominent choline-binding protein of the predicted size of
the full-length PspA of P833 (Fig. 4 B). Nucleotide se-
quence analysis of P833-FS1 showed the loss of two addi-
tional nucleotides upstream of the adenosine deletion in
P833 restored the in-frame expression of 
 
pspA
 
 (Fig. 3). As
P833-FS1 was the same serotype and the sequence of the
entire 
 
pspA
 
 was otherwise identical to P833, it was con-
cluded that this was a mutant of the same strain and that this
mutation most likely occurred in vivo. Thus, P833, a low-
passage clinical isolate from a child with otitis media, and
P833-FS1 recovered from the nasopharynx after carriage
for 40 d both had distinct frameshift mutations in 
 
pspA.
 
Recent reports suggest that PspA is a lactoferrin binding
protein (13). In contrast to the full-length PspA from
P833-FS1, neither P833 expressing the truncated protein
nor the purified PspA
 
31–189
 
 bound to human lactoferrin,
suggesting that human colonization does not require PspA-
mediated lactoferrin binding (Fig. 5). In an infant rat model
of nasopharyngeal colonization, a mixed inoculum of equal
numbers of P833 and P833-FS1 were compared (unpub-
lished data). P833-FS1 out-competed P833 by 48 h after
intranasal inoculation, suggesting that there is an advantage
to expression of the full-length PspA in carriage in the in-
fant rat, although expression of PspA
 
31–189
 
 is permissive for
human colonization.
 
Discussion
 
A number of pneumococcal protein vaccine candidates
have shown promise in animal studies, although no single
immunogen has emerged despite many years of investiga-
tion. The current study utilizes an experimental model of
colonization by an exclusive human pathogen in the natu-
ral host. We focused on the humoral immune response
Figure 4. Western blot analysis showing the stability of expression of PspA. Culture supernatants (A) and whole cell sonicates (B) obtained from the
last positive nasal or throat culture from each of the colonized subjects (FS#) were compared with the inoculation strain (lane I) by immunoblotting with
post-inoculation serum from subject FS31. The arrow indicates the position of the PspA31–189. The isolate recovered from one of the subjects (FS162) at
day 3 postinoculation was found to be a type 6A strain expressing a larger full-length PspA. This subject was then considered in the uncolonized group.
Size markers are in kilodaltons. 
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during nasopharyngeal colonization, the first step in the in-
teraction of the pneumococcus and humans. This approach
also allowed for the identification of protein targets against
which the presence of preexisting antibody may predict
susceptibility to carriage.
One of the key features of the experimental model of
carriage used in this study was the availability of preinocu-
lation samples. These sera permitted the identification of
targets of newly acquired antibody from among the many
antigens recognized by preexisting antibody in human se-
rum and secretions. Results of this limited study in 14
adults failed to support the hypothesis that the susceptibility
to carriage correlates with diminished levels of type-specific
anti-PS antibody (3, 17). Instead, susceptibility to coloniza-
tion was most closely associated with lack of preexisting
systemic (serum IgG) and mucosal (nasopharyngeal sIgA)
antibodies against a 22 kD protein subsequently identified
as the first 159 amino acids of mature PspA. No other anti-
gens with this characteristic could be detected when serum
and nasal washes were screened by Western analysis, a
technique limited in its sensitivity by the possibility of anti-
body against one protein obscuring another. In fact, if the
clinical isolate used in the inoculum did not express a trun-
cated form of PspA, allowing for the NH
 
2
 
-terminal portion
to be visualized separately from the more conserved
COOH-terminal portion, this association may not have
been detected (12). The fortuitous use of this natural PspA
mutant, however, enabled us to demonstrate a correlation
between the presence of preexisting antibody to PspA
 
31–189
 
and resistance to an intranasal challenge with the homolo-
gous strain. Based on this observation, this immunogenic
portion of PspA may be an important target of the immune
response to the pneumococcus during colonization and
would seem to offer promise as a vaccine component to
protect specifically against the acquisition of pneumococcal
carriage. PspA has previously been shown to be immuno-
genic and able to generate protection in colonization stud-
ies in mice (8, 18). In addition to providing corroborative
data in humans, the current study defines a smaller frag-
ment of 96 amino acids (PspA
 
93–189
 
) that may be sufficient
as an immunogen against carriage. This fragment of PspA,
however, is highly variable in sequence and does not con-
tain amino acids 192–260 previously shown to be impor-
tant in eliciting cross-protection in murine models (19). As
a result of the variability of the NH
 
2
 
-terminal region of
PspA, the correlation of preexisting antibody against
PspA
 
31–189
 
 and susceptibility to carriage appears to be strain-
specific. Our study, therefore, provides evidence to support
the immunization strategy proposed by Briles and others
based on a mixture of antigenically variable PspA molecules
representative of the most common clades but suggests that
a different region of PspA may contain the critical epitopes
for protection in humans (20).
Although it appears that the NH
 
2
 
-terminal portion of
PspA is highly immunogenic and that the immune response
to it may block the acquisition of carriage in the natural
host, the expression of PspA was noted to be unstable dur-
ing carriage. Such instability could be a limitation in devel-
opment of a PspA-based vaccine and we are currently ex-
amining the frequency of mutations in PspA in carriage
strains. This study shows that 
 
S. pneumoniae
 
 is able to colo-
nize and persist in the human nasopharynx for as long as 122 d
without expression of a full-length form of this major sur-
face protein. A thorough understanding of the contribution
of PspA to colonization and disease caused by this organism
is still lacking. Two features of PspA in the inoculum strain,
however, indicate that it was unlikely to have been fully
functional during colonization in 5/6 subjects; PspA
 
31–189
 
 is
secreted rather than anchored on the cell surface and it no
longer binds to lactoferrin, the only known ligand of PspA.
The observation that the challenge strain isolated from an
inflamed middle ear space and used in this human model of
experimental colonization expressed a truncated protein
could be evidence of prior selective immune pressure di-
rected against PspA. This escape mutation resulted in secre-
tion of an immunogenic fragment of PspA and loss of ex-
pression of the relatively conserved portions of the protein.
The frame-shift mutation in the inoculum strain occurred in
a run of eight tandem adenosines. Although not a particu-
larly long repetitive feature in this species with AT rich
DNA, tandem repeats are known to be subject to increased
rates of mutation by a mechanism involving slip-stranded
mispairing (21). In contrast, the last isolate cultured from 1/6
colonized subjects had a second mutation site that restored
the expression of a full-length protein. The in vivo instabil-
ity of expression and frequency of mutations in PspA or
other pneumococcal antigens has not been recognized pre-
viously. Therefore, the use of experimental carriage studies
performed in humans allowed for the identification of a po-
tentially protective immunogen as well as demonstrating a
naturally occurring variability in its expression. This study
offers a paradigm for using experimental human infection to
characterize the immune response to a pathogen and to
identify and/or confirm vaccine targets.
Figure 5. Lactoferrin binding by S. pneumoniae. Binding of lactoferrin
to extracted choline-binding proteins was detected with an antiserum to
human lactoferrin. P282 (PspA ; lane 1), P282::pspA  (lane 2), P833 (in-
oculation strain; lane 3), last isolate from subject FS1 expressing a full-
length PspA (lane 4), a type 6A strain isolated from subject FS162 (lane
5), purified human lactoferrin control (lane 6), and the purified NH2-ter-
minal fragment of PspA (lane 7). Size markers are in kilodaltons.365 McCool et al. Brief Definitive Report
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